177 related articles for article (PubMed ID: 11025866)
1. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
Cho L; Marso SP; Bhatt DL; Topol EJ
J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
[TBL] [Abstract][Full Text] [Related]
3. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
4. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
[TBL] [Abstract][Full Text] [Related]
8. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ;
Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
10. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
[TBL] [Abstract][Full Text] [Related]
11. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ;
Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954
[TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
14. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
[TBL] [Abstract][Full Text] [Related]
15. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
[TBL] [Abstract][Full Text] [Related]
16. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
EPISTENT Investigators
Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
[TBL] [Abstract][Full Text] [Related]
17. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
Stuckey TD; Stone GW; Cox DA; Tcheng JE; Garcia E; Carroll J; Guagliumi G; Rutherford BD; Griffin JJ; Turco M; Lansky AJ; Mehran R; Fahy M; Brodie BR; Grines CL;
Am J Cardiol; 2005 Jan; 95(1):1-7. PubMed ID: 15619385
[TBL] [Abstract][Full Text] [Related]
18. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
19. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
